Physician profile

Scott A Matthews

Primary Podiatric Medicine · Portsmouth, OH

NPI 1770512295

$479.24

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$65.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $124.25 2019
Treace Medical Concepts, INC. $112.90 2022
Grt US Holding, INC. $80.25 2022
Paratek Pharmaceuticals, INC. $50.00 2023 Nuzyra
Melinta Therapeutics, LLC $41.57 2019
Triad Life Sciences INC. $29.71 2022
Smith+Nephew, INC. $25.13 2019-2021
Organogenesis INC. $15.43 2023 Puraply

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott A Matthews

$479.24

in general payments reported 2019-2025

Years
2019-2023
Top company
Horizon Therapeutics Plc

https://glasscript.com/doctor/216347/scott-a-matthews

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.